These CSF metabolites are not able to discriminate between AD and non-AD groups, although some of them correlate with neuropsychological evaluations, as well as standard AD CSF biomarkers (β-amyloid, p-Tau). This evidence concerns the gene MAPT and Alzheimer disease.